Identification of molecular subtypes and prognostic model to reveal immune infiltration and predict prognosis based on immunogenic cell death-related genes in lung adenocarcinoma-Reference-Cited by-同舟云学术

Identification of molecular subtypes and prognostic model to reveal immune infiltration and predict prognosis based on immunogenic cell death-related genes in lung adenocarcinoma

Published:2023-12-17 Issue:23-24 Volume:22 Page:2566-2583
ISSN:1538-4101
Container-title:Cell Cycle
language:en
Short-container-title:Cell Cycle

Author:

Dong Yinying¹,Yu Xiao²,Song Hao¹,Chen Qingfeng³,Zheng Bin⁴,Ji Xiaomeng¹,Xu Mingjin¹,Liu Jian⁵,Sun Xiangyin¹,Wang Qiuxiao¹,Ren Ruimei¹,Lu Haijun¹

Affiliation:

1. Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China

2. Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, China

3. Breast Disease Diagnosis and Treatment Center, The Affiliated Hospital of Qingdao University, Qingdao, China

4. Department of Neurosurgery, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China

5. Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China

Funder

National Natural Science Foundation of China

Chinese Society of Clinical Oncology

Natural Science Foundation of Shandong Province in China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384101.2023.2300591

Reference54 articles.

1. Cancer statistics, 2023

2. Expanding Horizons for Treatment of Early-Stage Lung Cancer

3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

4. Current status of immune checkpoint inhibition in early-stage NSCLC

5. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer